Division of Gynecology, Department of Surgery, Boston Children's Hospital, Boston, MA, USA.
Division of Adolescent Medicine, Department of Pediatrics, Penn State Health Children's Hospital, Hershey, PA, USA.
Womens Health (Lond). 2024 Jan-Dec;20:17455057241265081. doi: 10.1177/17455057241265081.
Danazol is a synthetic progestin with androgenic effects that is approved by the Food and Drug Administration for treatment of endometriosis, benign fibrocystic breast disease, and hereditary angioedema. In recent years, increasing numbers of transgender and nonbinary individuals seeking menstrual suppression have been offered danazol due to its potential to both induce amenorrhea and cause reversible androgenic side effects including pigmentation of vellus hairs and voice changes, which may be desirable in this population. There are currently no studies assessing use of danazol within the transgender population for menstrual suppression.
This study's primary aim was to evaluate the use of danazol as a menstrual suppression agent in transgender patients.
This was a retrospective multisite cohort study of all individuals who had been on danazol at two tertiary care centers between 2000 and 2022.
All patients prescribed danazol were identified using a search of the electronic medical records. For demographic purposes, comparisons were made between those who did and did not use danazol for the purpose of menstrual suppression. A detailed chart review was then performed to analyze the experiences of menstrual suppression in transgender and nonbinary patients.
Most transgender and nonbinary patients on danazol for menstrual suppression remained on it at their most recent follow-up visit, and many charts noted improvements in gender dysphoria, pelvic pain, dysmenorrhea, endometriosis, and heavy menstrual bleeding. Most transgender patients achieved amenorrhea.
Danazol may be a reasonable option for menstrual suppression in transgender and nonbinary patients. Our findings show its potential to not only induce amenorrhea but cause desired androgenic symptoms and improve gender dysphoria, pelvic pain, dysmenorrhea, endometriosis, and heavy bleeding. While the androgenic effects of danazol are less desirable in cisgender populations, it is an attractive option for menstrual suppression in transgender and nonbinary patients.
达那唑是一种具有雄激素作用的合成孕激素，已被美国食品和药物管理局批准用于治疗子宫内膜异位症、良性纤维囊性乳腺疾病和遗传性血管性水肿。近年来，越来越多寻求抑制月经的跨性别和非二元个体被提供达那唑，因为它既能诱导闭经，又能引起可逆的雄激素副作用，包括毳毛色素沉着和声音变化，这在该人群中可能是理想的。目前，没有研究评估达那唑在跨性别人群中用于抑制月经的用途。
本研究的主要目的是评估达那唑作为抑制月经的药物在跨性别患者中的应用。
这是一项回顾性多中心队列研究，纳入了 2000 年至 2022 年期间在两个三级保健中心接受达那唑治疗的所有个体。
通过电子病历搜索确定所有接受达那唑治疗的患者。为了进行人口统计学比较，对那些为了抑制月经而使用达那唑和那些未使用达那唑的患者进行了比较。然后对详细的图表进行了回顾分析，以分析跨性别和非二元患者的月经抑制经验。
大多数接受达那唑抑制月经的跨性别和非二元患者在最近一次随访时仍在使用达那唑，许多图表记录了性别焦虑、盆腔疼痛、痛经、子宫内膜异位症和月经过多的改善。大多数跨性别患者达到闭经。
达那唑可能是跨性别和非二元患者抑制月经的合理选择。我们的研究结果表明，它不仅能诱导闭经，还能引起所需的雄激素症状，并改善性别焦虑、盆腔疼痛、痛经、子宫内膜异位症和月经过多。虽然达那唑的雄激素作用在顺性别人群中不太理想，但它是跨性别和非二元患者抑制月经的一个有吸引力的选择。
